Skip to content

Uterine artery embolization versus hysterectomy for symptomatic adenomyosis: a case-control study

Uterine artery embolization versus hysterectomy for symptomatic adenomyosis: a case-control study - QUESTA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55436
Enrollment
100
Registered
2015-07-27
Start date
2015-11-17
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis endometrium in uterine wall muscle.

Interventions

UAE, performed by experienced interventional radiologists versus hysterectomy (laparoscopically, abdominally or vaginally).

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Premenopausal women with symptomatic adenomyosis or dominant adenomyosis in combination with fibroids. • Woman who are (due to complaints and non responsive former treatment strategies) eligible for hysterectomy • No wish to conceive • Able to understand Dutch or English language.

Exclusion criteria

Exclusion criteria: • Younger than 18 years of age • Pelvic infection/Suspicion or presence of malignancy • Current pregnancy • Contra-indication for angiography (such as contrast fluid allergy, coagulopathy and renal failure), when not treatable • Deep infiltrating endometriosis requiring surgery or with risks on intestinal stenosis • Concurrent removable submucous fibroids (Patients eligible after removal)

Design outcomes

Primary

MeasureTime frame
Primary endpoint: quality of life as measured by a combination of the World Health Organization Quality-of-Life Scale (WHOQOL-Bref) and short-form-12 (SF-12) questionnaire at 26 weeks after therapy.

Secondary

MeasureTime frame
The two treatments will also be compared in terms of Clinical outcomes, Recovery related outcomes, Quality of life outcomes and cost outcomes. Also imaging outcomes will be investigated at baseline in order to identify potential predictive parameters for therapy effect.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 5, 2026